Literature DB >> 22492705

The impact of effective continuous positive airway pressure on homeostasis model assessment insulin resistance in non-diabetic patients with moderate to severe obstructive sleep apnea.

Dan Yang1, Zhihong Liu, Haixing Yang.   

Abstract

Previous studies on the effects of continuous positive airway pressure (CPAP) on homeostasis model assessment insulin resistance (HOMA-IR) in obstructive sleep apnea patients have yielded conflicting results. Therefore, we conducted this meta-analysis to evaluate the impact of effective CPAP on HOMA-IR in non-diabetic patients with moderate to severe obstructive sleep apnea. We searched PubMed, HighWire Press, Ovid Medline (R), Cochrane library and EMBASE before December 2011 on original English language studies. The data on HOMA-IR and body mass index (BMI) were extracted from these studies. As compared with baseline values, 8 to 24 weeks of effective CPAP (>4 h/night) treatment significantly reduced HOMA-IR by an average of 0.75(95% CI, from -0.96 to -0.53; p < 0.001). However, in subjects with irregular CPAP (<4 h/night), this effect was not observed (-0.22; 95%CI, from -2.24 to 1.80; p = 0.83). There were no intervention-related changes in BMI in both regular and irregular CPAP. Our analysis showed that 8 to 24 weeks of effective CPAP could significantly improve HOMA-IR in non-diabetic patients with moderate to severe obstructive sleep apnea, while no significant changes in BMI were detected. Further large scale, randomized and controlled trials are needed to evaluate the longer treatment and its possible effects on weight control and cardiovascular disease.
Copyright © 2012 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22492705     DOI: 10.1002/dmrr.2301

Source DB:  PubMed          Journal:  Diabetes Metab Res Rev        ISSN: 1520-7552            Impact factor:   4.876


  9 in total

1.  Obstructive Sleep Apnea Risk, Asthma Burden, and Lower Airway Inflammation in Adults in the Severe Asthma Research Program (SARP) II.

Authors:  Mihaela Teodorescu; Oleg Broytman; Douglas Curran-Everett; Ronald L Sorkness; Gina Crisafi; Eugene R Bleecker; Serpil Erzurum; Benjamin M Gaston; Sally E Wenzel; Nizar N Jarjour
Journal:  J Allergy Clin Immunol Pract       Date:  2015-05-21

Review 2.  Obstructive Sleep Apnoea and Type 2 Diabetes.

Authors:  Abd A Tahrani; Asad Ali
Journal:  Eur Endocrinol       Date:  2014-02-28

Review 3.  Effect of CPAP therapy on liver disease in patients with OSA: a review.

Authors:  Xin Liu; Yuyang Miao; Fan Wu; Tingting Du; Qiang Zhang
Journal:  Sleep Breath       Date:  2018-01-11       Impact factor: 2.816

4.  Meta-analyses of the Association of Sleep Apnea with Insulin Resistance, and the Effects of CPAP on HOMA-IR, Adiponectin, and Visceral Adipose Fat.

Authors:  Imran H Iftikhar; Camilla M Hoyos; Craig L Phillips; Ulysses J Magalang
Journal:  J Clin Sleep Med       Date:  2015-04-15       Impact factor: 4.062

5.  Insulin Resistance and Hypertension in Obese Youth With Sleep-Disordered Breathing Treated With Positive Airway Pressure: A Prospective Multicenter Study.

Authors:  Sherri L Katz; Joanna E MacLean; Lynda Hoey; Linda Horwood; Nicholas Barrowman; Bethany Foster; Stasia Hadjiyannakis; Laurent Legault; Glenda N Bendiak; Valerie G Kirk; Evelyn Constantin
Journal:  J Clin Sleep Med       Date:  2017-09-15       Impact factor: 4.062

Review 6.  Insulin resistance, glucose intolerance and diabetes mellitus in obstructive sleep apnoea.

Authors:  Brian D Kent; Walter T McNicholas; Silke Ryan
Journal:  J Thorac Dis       Date:  2015-08       Impact factor: 2.895

7.  Pro: should asymptomatic patients with moderate-to-severe OSA be treated?

Authors:  Silke Ryan
Journal:  Breathe (Sheff)       Date:  2019-03

Review 8.  Obstructive Sleep Apnoea and Vascular Disease in Patients with Type 2 Diabetes.

Authors:  Abd A Tahrani
Journal:  Eur Endocrinol       Date:  2015-08-19

Review 9.  Sleep apnea and type 2 diabetes.

Authors:  Isao Muraki; Hiroo Wada; Takeshi Tanigawa
Journal:  J Diabetes Investig       Date:  2018-04-14       Impact factor: 4.232

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.